Conferences  >  Life Sciences  >  Molecular Biology  >  United Kingdom

The Company of Biologists Ltd

This Workshop will focus on the biology of toxic metabolites in the ageing process, stem cells and cancer. Specific emphasis will be placed on how metabolites that carry carbonyls (such as aldehydes and ketones) damage stem and cancer cells. A particular area will focus on endogenous aldehydes (such as acteladehyde, formaldehyde and methyl-gyoxal), the enzymes that remove them [aldehyde dehydrogenases (Aldh) and functionally related glutathione-based enzymes such as Adh5 and Glo-1/2]. Further, we will consider how human genetic variation can contribute to metabolite sensitivity, and how mutations in cancer genomes in toxic metabolism pathways can be exploited for therapy.

The Company of Biologists Ltd

This Workshop unites experts in human cell fate engineering and experts in the manipulation and characterisation of single cells. The goal is to fully understand the molecular steps underlying the transformation of one cellular identity into another. The cross-disciplinary selection of speakers spans the fields of cell fate engineering and emerging technologies to analyse and manipulate cells at single-cell resolution.

Direct lineage reprogramming approaches, Assessment of reprogramming inefficiency and infidelity, Engineering cells with defined identity through new methods, De novo predictions of factors and conditions for target cell type generation

Cambridge Healthtech Institute

The ubiquitin-proteasome, lysosome and autophagy systems are all well-controlled, selective degradation pathways that are key cellular regulators in cancer, CNS, and other diseases. A new generation of hetero bi-functional chimeras and small molecule monovalent degraders are being developed to hijack these systems for targeted protein degradation or stabilization. These molecules that include Proteolysis-targeting chimeras (PROTACs) and molecular glues are being used to seek out previously “undruggable” targets for therapeutic intervention. However, challenges do exist in terms of specificity, stability, biodistribution and penetration of these degrader molecules. This conference on Next-Generation Degraders & Glues brings together experts in the field to discuss these new therapeutic modalities, as well as issues underlying the use of targeted degradation as a new therapeutic approach.

Marketing Manager;     Email: aorktiese@healthtech.com

PROTACs, Molecular Glues, Protein Degradation

Isaac Newton Institute for Mathematical Sciences (INI)